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Abstract
Alzheimer’s disease (AD) is a major dementia related to an overproduction of free
radicals (FRs), which leads to the generation of oxidative stress in brain tissue. Amyloid
beta-peptide of 42 amino acid residues (Aβ1–42) is the main source of FRs in patients with
AD. βA1–42 results from hydrolysis of the amyloid precursor protein by β-secretase in a
process known as the amyloidogenic pathway. During βA1–42 aggregation, the peptide
interacts with various transition metals to produce hydrogen peroxide (H2O2) by the
Fenton reaction, generating the hydroxyl radical (•OH), which damages lipids, proteins,
and nucleic acids, thereby contributing to neurodegeneration. In addition, βA1–42  is
recognized by microglial receptors; it activates these cells, causing overproduction of
superoxide anion (O2•−) by NADPH oxidase; O2•− is also converted into H2O2 and finally
to •OH in the Fenton reaction. Other factors that contribute to oxidative stress during
microglial activation are the overproduction of nitric oxide and interleukins and the
overexpression of some enzymes, including cyclooxygenase and inducible nitric oxide
synthase, all of which contribute to FR production. Currently, various models in vitro
and in vivo exist that permit quantification of O2•− and H2O2 and determination of the
effects of these reactive oxygen species.
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1. Introduction
Alzheimer’s disease (AD) is a chronic pathology, the development and progression of which
has been related to free radical (FR) production such as occurs in diabetes, cancer, and other
diseases secondary to molecular damage. AD is characterized by neuronal damage associated
with  an  overproduction  of  free  radicals  (FRs).  Although  several  hypotheses  have  been
advanced to explain the memory loss that occurs in AD, the most accepted theory is that
neuronal damage is associated with the presence of aggregates of the amyloid beta peptide
of 42 residues (Aβ1–42) that is related to FR production.
It is known that Aβ aggregation contributes to FR production because Aβ molecules are able
to bind metals such as copper (cupric ion, Cu2+) that are present at high concentrations in the
brains of patients with AD. Cu2+ leads to the formation of hydrogen peroxide (H2O2), which is
a reactive oxygen specie (ROS). In turn, H2O2 reacts with other metals such as iron (Fe2+)
through the Fenton reaction, producing the hydroxyl radical (•OH), which damages mem-
brane lipids, proteins, and other biomolecules. Here, it is important to remember that ROS
include not only FRs such as •OH, superoxide anion (O2•−), and others but also non-FRs such
as H2O2, ozone (O3), and hypochlorous acid (HOCl). One hypothesis suggests that the ROS
produced during AD hydrolyze a significant amount of acetylcholine (ACh), reducing
cholinergic neurotransmission and thereby contributing to memory loss [1]. This has justified
the use of acetylcholinesterase (AChE) inhibitors to treat AD; however, these drugs have shown
limited clinical results [2].
Brain tissue is especially susceptible to oxidative stress due to its high aerobic metabolic activity
and high lipid content. Oxidative stress is defined as the loss of cell homeostasis provoked by
an imbalance between the production of prooxidant molecules (ROS) and the activity of
antioxidant defense systems. Under physiological conditions, ROS are present at low concen-
trations in tissues, where they act as signaling molecules during cell growth, cell proliferation,
redox homeostasis, and cellular signal transduction (activating tyrosine kinases, MAPKs
(mitogen-activated protein kinases), or Ras protein) [3]. However, higher concentrations of
ROS lead to a pathophysiological condition produced by an oxidative stress state.
It has been reported that AD is associated with a high level of oxidative stress and lowered
antioxidant defenses. Thus, AD may be due to the presence of FRs that alter metal metab-
olism and result in Aβ aggregation toxicity [4]. In recent years, considerable research has
focused on the amyloid fibrils that are produced in AD, and it has been shown that the
structures of these aggregates are more complex than the linear addition of monomers to
fibrils; in fact, a variety of Aβ aggregates have been described. Furthermore, the amyloid
fibrils cause the formation of several toxic intermediates, including soluble oligomers that
bind to hippocampal neurons to produce dysfunctions in synaptic plasticity and conse-
quently contribute to the development of AD [5]. Hence, great efforts have been made to
find ways to prevent Aβ aggregation because the oligomers and fibrils are also able to
activate the NADPH oxidase in microglial cells, which are “like macrophage cells” in the
brain. NADPH oxidase can produce great quantities of O2•−, which is converted to H2O2;
this, in turn, can participate in the Fenton reaction, producing •OH. Thus, the generation of
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FRs is important in AD because these have been related to its development, and Aβ and
NADPH oxidase may be key targets for the treatment of this disease.
In this chapter, we describe the important implications of FRs in the development and
progression of AD. First, we discuss some of the principal biomolecules involved in the
production of FRs in AD, emphasizing the role of Aβ1–42 due to its aggregation and its conse-
quent implication in the formation of senile plaques when it reacts with metals to produce
ROS. In addition, we explain how Aβ participates in microglial activation to produce more
FRs due to the activity of NADPH oxidase. Subsequently, the reactions in which the ROS
produced by Aβ and NADPH oxidase participate are described, and the relationship between
FR production and the neuronal damage that occurs during AD is explained. Finally, we
discuss how •OH and H2O2 production can be determined using various experimental
techniques in vitro and in vivo.
2. Biomolecules involved in free radical production in Alzheimer’s disease
2.1. Amyloid beta formation
Aβ is the principal component of extracellular deposits called amyloid plaques that are present
in the brains of patients with AD. According to the amyloid cascade hypothesis, which was
first established in 1991, Aβ accumulation represents the critical step in the pathophysiology
of AD [6]. Aβ originates from the processing of a large transmembrane glycoprotein, amyloid
precursor protein (APP). APP is a single-pass transmembrane protein with a large extracellular
domain. Alternate splicing of the APP transcript generates eight isoforms, the three most
common of which are the 695-amino acid form, which is expressed predominantly in the
central nervous system (CNS), and the 751- and 770-amino acid forms, which are more
ubiquitously expressed [7].
The precise physiological function of APP is not known and remains one of the vexing issues
in the field. In most studies, APP overexpression shows a positive effect on cell health and
growth [8]. APP can be hydrolyzed following both the non-amyloidogenic and the amyloido-
genic pathways, depending on the enzymes involved. In the non-amyloidogenic pathway, APP
is hydrolyzed at amino acid residue 83 from the C-terminus by α-secretase (Figure 1). This
cleavage produces a fragment of 83 amino acids (C83) and a large N-terminal ectodomain
(sAPPα). C83 remains in the membrane, where it is hydrolyzed by the γ-secretase complex to
produce p3, a short fragment, and the APP intracellular domain (AICD). In the amyloidogenic
pathway, APP is hydrolyzed at amino acid residue 99 from the C-terminus by β-secretase to
produce a fragment of 99 amino acids (C99) and an sAPPβ fragment. C99 remains in the
membrane, where it is hydrolyzed by the γ-secretase complex, releasing the Aβ peptide, which
consists of 42 amino acid residues (Aβ1–42), and other peptides (Figure 1) [9]. The principal
difference between these two pathways is that α-secretase cleavage occurs within the Aβ
region, avoiding the formation of Aβ peptide, whereas β-secretase cleavage permits Aβ
formation from APP.
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Figure 1. Hydrolysis of APP to produce the Aβ peptide. When Aβ1–42 is released, it tends to aggregate to form oligom-
ers and fibrils; these subsequently react with metals or with microglial cells and produce a large amount of ROS.
It is important to mention that under physiological conditions, both of these pathways occur;
in fact, it has been demonstrated that Aβ is an enhancer of learning and memory and that low
doses of Aβ produce presynaptic enhancement [10]. It was shown that concentrations of Aβ
peptides in the picomolar-nanomolar range decrease the synthesis and release of ACh without
causing neurotoxicity. The potency and reversible nature of this effect and the low concentra-
tions of Aβ peptides found in normal brain cells suggest that Aβ-related peptides may act as
modulators of cholinergic function under normal conditions [11]. However, during AD, the
increase in the concentration of Aβ may be the result of an overproduction and/or a deficiency
in its elimination, resulting in Aβ aggregation [12]. During the processing of APP by the
amyloidogenic pathway, two principal Aβ species are produced: Aβ of 40 amino acid residues
and Aβ of 42 amino acid residues (Aβ1–40 and Aβ1–42, respectively). Despite the difference of
only two amino acids, the latter is more prone to aggregate; the additional amino acids give
Aβ1–42 distinct thermodynamic properties [13].
Two distinct mechanisms have been proposed to explain the formation of Aβ fibrils. The first
invokes nucleated polymerization in which Aβ polymerization creates a nucleus to which
monomers are added in an elongation process (Figure 2).
The second proposed mechanism is based on a nucleated conformational conversion in which
oligomers are formed as intermediates; these intermediates then form protofibrils that
subsequently assemble into fibrils [14]. Because Aβ oligomers have been implied in the
pathophysiology of AD, it has been proposed that the second mechanism contributes more to
the progression of the disease. However, although enormous efforts have been made to
understand how Aβ aggregates, principally in the form of Aβ1–42, which is more cytotoxic than
Aβ1–40 [15], the mechanism by which Aβ1–42 undergoes conformational changes to form
oligomers and protofibrils remains unknown (Figure 2).
Recently, several experimental techniques such as nuclear magnetic resonance (NMR) (solid
state), Fourier transform infrared spectroscopy (FTIR), cryo-electron microscopy (cryo-EM),
single-touch atomic force microscopy (AFM), and fluorescence have allowed investigators to
study the Aβ1–42 fibril formation process in detail. The results suggest that a nucleated confor-
mational conversion occurs when Aβ1–42 is present at high concentrations (>20–30 μM). The
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predominant oligomers formed in the early step of aggregation are dimers, tetramers,
pentamers, and hexamers, but their formation is temperature- and concentration dependent.
At approximately 15°C and high Aβ1–42 concentration, the formation of protofibrils from
oligomers occurs more rapidly. The principal conformational change is observed in the lateral
association of oligomers to yield protofibrils; this conformation involves conversion from a
random coil structure to a β-sheet via an antiparallel β-hairpin intermediate [16]. The antipar-
allel β-hairpin has intramolecular hydrogen bonds between two hydrophobic β-strands, one
with an LVFF sequence and another with a GLMVG sequence at the C-terminus. However,
conversion to a β-sheet involves the rotation of β-strands to form intermolecular hydrogen
bonds with other monomers in the Aβ1–42 structure. It is known that the β-strands adopt a
parallel orientation in the Aβ1–42 fibrils. The β-sheet is stabilized by intermolecular hydrogen
bonds as well as by intramolecular and intermolecular interactions between the residue side
chains in the β-strands. It has been confirmed that the formation of the antiparallel β-hairpin
is a rate-determining step in fibril formation, with the interaction between aspartate 23 (Asp23)
and lysine 28 (Lys28) being the most important.
Figure 2. Proposed mechanisms of Aβ fibril formation. Left: nucleated polymerization at low Aβ concentrations. Right:
nucleated conformational conversion at high Aβ concentrations. The latter mechanism is considered to be more related
to the progression of AD because it produces a large amount of oligomers, which, together with the fibrils, are cytotox-
ic.
Other recent studies show that there are differences in Aβ1–42 and Aβ1–40 fibril formation [17].
One of these differences is that the Aβ1–42 fibril has a triple β-motif that consists of three β-sheets
(β1: 12–18; β2: 24–33; β3: 36–40); thus, this structure differs from the proposed β-loop-β motif
structure for Aβ1–40 fibrils. Additionally, the reported structure of Aβ1–42 fibrils differs from that
of Aβ1–40 fibrils from the brain, which have a U-shaped topology with Asp 23-Lys 28 forming
a salt bridge and fewer β-regions [18]. Furthermore, in Aβ1–42 fibrils a salt bridge between Lys28
and the carboxylate of the C-terminal alanine (Ala42) was identified; this is important because
it shows that Ala42 and not Asp 23, as had been proposed, stabilizes the salt-bridge interaction.
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Although several models of Aβ1–42 fibrils have been described, to date no Aβ1–42 fibril structure
has been obtained from the brain, and all that is known about the conformational structure of
Aβ1–42 fibrils has been obtained from synthetic Aβ1–42. Therefore, all Aβ1–42 models and obser-
vations are approximations that should be accepted with caution because Aβ1–42 fibril forma-
tion may be influenced by temperature, pH, and other biochemical parameters that are not
considered when the fibrils are formed in vitro. For example, it was recently reported that
calcium (Ca2+) interacts with glutamate 22 (Glu22) and the phospholipid bilayer to accelerate
Aβ1–42 aggregation [19]. Furthermore, this type of interaction between a cation and Glu22 could
also be important in interactions of the peptide with metals such as Cu2+, which at some
concentrations favors Aβ1–42 aggregation. Therefore, it is difficult to propose a definite and
unique Aβ1–42 fibril structure that could provide a basis for elucidating the steps involved in
Aβ1–42 aggregation.
As mentioned previously, the mechanism of Aβ1–42 aggregation that has been proposed to
contribute principally to the pathogenesis of AD is nucleated conformational change due to
the formation of oligomers of Aβ1–42 [20]. When the amyloid hypothesis was first proposed,
it was postulated that only Aβ1–42 fibrils were the toxic form of Aβ; however, it is now
known that both oligomers and protofibrils are toxic species and that oligomers are more
toxic than fibrils [21]. This has been generally accepted due to the finding that cognitive def-
icits are better correlated with the amount of soluble Aβ than with the number of amyloid
plaques; thus, neurodegeneration is not a consequence of amyloid deposition [22]. This is
consistent with the oxidative damage produced by the Aβ1–42 oligomers. There are several
hypotheses related to Aβ1–42 aggregation and ROS production during AD development and
progression. The results of a number of studies support the hypothesis that Aβ1–42 genesis
depends on ROS production, whereas other reports suggest that Aβ1–42 is capable of forming
ROS [23]. In addition, some previous evidence clearly shows an association between AD
and the ROS produced by Aβ1–42 oligomers and metals (Figure 1). Hence, some studies have
focused on searching for strategies to avoid the oligomerization of Aβ1–42 by inhibiting it or
by decreasing ROS production through the design of multi-targeted compounds; this has
resulted in a promising approach [8]. By targeting at this molecular level, it is possible to
avoid Aβ1–42 aggregate formation, which functions as a signal that activates microglial cells
and initiates an innate immune response that results in the production of high levels of cyto-
kines and ROS.
2.2. Microglial activation enhances NADPH oxidase activity
Due to their phagocytic activity, microglial cells represent the macrophages of the brain; for
this reason, they are regarded as the predominant immune cells in the brain. In the healthy
brain, these cells act as resting microglia, maintaining their ramified morphology and protect-
ing the brain from pathogens by removing them by phagocytosis [24]. However, when
microglial cells detect a sign such as a pathogen associated with molecular patterns (PAMPs)
or damage associated with molecular patterns (DAMPs), the microglia are activated to acquire
a wide range of phenotypes. Two classical phenotypes are the pro-inflammatory M1 phenotype
(induced by pro-inflammatory cytokines and/or TLR activation (Toll-like receptor)) and the
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non-inflammatory M2 phenotype (induced by interleukin (IL)-4), according to the classifica-
tion for macrophages outside the brain [25]. Aβ1–42 oligomers and fibrils interact with SCARA1,
CD36, CD14, a6β1 integrin, CD47, TLR2, TLR4, TLR6, and TLR9 receptors on the microglia;
when Aβ1–42 interacts with TLR or CD receptors, the expression of inducible nitric oxide
synthase (iNOS), cyclooxygenase 2 (COX2), tumor necrosis factor (TNF)-alpha, IL-1β, IL-6, etc.
is induced, resulting in a dysregulated immune response that contributes to neurodegenera-
tion [26].
Furthermore, it was found that low concentrations of Aβ1–42 induce microglial proliferation
and cause release of H2O2 and O2•− to the extracellular space due to the activation of NADPH
oxidase (Figure 3A) [27]. The fact that NADPH oxidase 2 (NOX2) is widely distributed in
microglial cells and neurons has been corroborated in in vitro and in vivo models using
microglia derived from NOX2 knockout mice and the NOX2 inhibitors diphenyleneiodonium
(DPI) and apocynin [28]. In microglial cells, NOX2 is activated only after the binding of Aβ
oligomers to the Mac receptor (Mac-1), an integrin receptor also known as CD11b/CD18,
complement receptor 3 or aMβ2 that is important during reactive microgliosis and in neuro-
degeneration (Figure 3B) [29, 30].
Figure 3. Pro-inflammatory factors produced by the interaction of Aβ1–42 oligomers with TLR or Mac-1 receptors. (A)
Aβ1–42 oligomers induce the activation of NADPH oxidase. (B) Production of cytokines induced by the interaction of
Aβ1–42 oligomers with the TLR receptor.
It is currently known that unique NADPH oxidase activity is associated with the generation
of O2•− or H2O2, depending on the isoform. The confirmation of NADPH oxidase participation
in microglial activation and the consequent production of ROS were obtained using cells from
patients with chronic granulomatous disease (CGD). Because this disease is characterized by
the inability of cells to produce H2O2 due to mutations in the genes that encode the subunits
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of NADPH oxidase, monocytes and neutrophils from CGD patients fail to produce ROS in
response to fibrillary Aβ peptides [31, 32].
Park et al. assessed ROS production in the neocortex using hydroethidine fluoromicrography
[29]. Fibrillar Aβ superfused through a cranial window increased ROS production in the
neocortex. This effect could be abolished by the addition of a peptide inhibitor of the gp91phox
subunit. These authors further demonstrated that ROS levels were increased in the Tg2576
mouse model of AD; however, no signs of ROS production were evident in a mouse model in
which Tg2576 mice lacked the gp91phox gene.
NOX2 is an oligomeric protein composed of three cytosolic subunits (p60phox, p47phox, and
p40phox) and two transmembrane subunits (p91phox and p22phox). For the production of
O2•− by NOX2, p22phox must form a complex with p47phox. It has been demonstrated that,
in primary microglial cells and monocytes exposed to fibrillar Aβ, p47phox and p67phox
subunits are translocated from the cytosol to the membrane, favoring the enhanced activity of
NADPH oxidase [33].
The production of O2•− together with the neurotoxic factors PGE2, IL-β1, TNF-alpha, H2O2,
nitric oxide (NO), and peroxynitrite (ONOO−) can result in neuronal death [34]. Subsequently,
the O2•− produced by NOX2 reacts with NO generated by iNOS to form ONOO−. In the presence
of excessive amounts of NO, nitration and S-nitrosylation of several proteins, as well as
dityrosine formation, occur. Tyrosine 10 of Aβ can undergo nitration, which in turn increases
the probability of Aβ aggregation; this is shown by the fact that Aβ nitrotyrosine has been
found in amyloid plaques [35].
During chronic neuroinflammation, microglia maintain the transcription of mRNAs coding
for pro-inflammatory factors such as NOX2, iNOS, TNF-alpha, IL-1β, and COX2. The interac-
tion between Aβ1–42 oligomers and TLR receptors begins the phase of neurodegeneration
(Figure 3B); as neuroinflammation progresses, the interaction between Aβ1–42 oligomers and
Mac-1 receptors results in the production of large amounts of FRs such as O2•−, which is
converted to H2O2 to maintain the neuroinflammation (Figure 3A).
O2•− dismutates spontaneously or by an enzymatic reaction catalyzed by superoxide dismutase
(SOD), an enzyme that can scavenge O2•− and convert it into H2O2 [36]. Because O2•− is the
primary ROS produced during the neuroinflammatory process, this is considered to play a
key role in the activation of microglia and the activation of NADPH oxidase. However, O2•−
can also be produced by xanthine oxidase and during mitochondrial respiration. The O2•− can
reduce and liberate ferric ion (Fe3+) from ferritin or ferrous ion (Fe2+) from iron-sulfur clusters.
This reaction is of great importance because Fe2+ participates in the Fenton reaction and
produces •OH. O2•− contributes to the Fenton reaction via the Haber-Weiss reaction, in which
O2•− reduces Fe3+ produced in the Fenton reaction to Fe2+ and maintains iron (II), thereby
facilitating the Fenton reaction. The net Haber-Weiss reaction is as follows (1-3):
3 2 2
2 2+Fe / Cu O Fe / Cu O-+ + + ++ ®g (1)
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2 3 2
2 2Fe Cu H O Fe / Cu OH O+ +/ H++ + + + -® g (2)
2 2 2 2O H O O OH OH+ -- +® +gg (3)
Numerous experimental studies have shown that Aβ oligomers are more toxic than Aβ fibrils,
and that ROS are produced from the beginning of AD, playing a crucial role in neuroinflam-
mation.
3. Biochemical and chemical reactions in Alzheimer’s disease that yield
free radicals
3.1. Metal dyshomeostasis during Alzheimer’s disease
It is well known that certain transition metals are essential for neural function. The levels and
transport of these metals are strictly regulated by the blood-brain barrier (BBB), and disruption
of metal homeostasis in the brain is thought to play an important role in the pathogenesis of
AD [37]. The principal areas of the brain in which metals tend to accumulate are the hippo-
campus, the amygdala, and the cerebrospinal fluid (CSF); in some of these areas, both senile
plaques and neurofibrillary tangles are found (Table 1).
The mammalian brain contains an intrinsically high concentration of copper (Cu2+), zinc (Zn2+),
and iron (Fe2+) ions compared to other tissues due to its high requirement for numerous metal-
dependent enzymes and metal-dependent metabolic processes [38]. Not only has dyshomeo-
stasis of Cu2+, Zn2+, and Fe2+ been linked with AD but it has also been reported that senile
plaques are related to high concentrations of these metals as well as of chrome (Cr3+) and
cadmium (Cd2+) (Table 1) [39–41]. Furthermore, these metals are involved in FR production
by their participation in the Fenton and Fenton-like reactions; importantly, it has been
suggested that they may interact with biomolecules implicated in AD such as Aβ, AChE, and
ACh [1], with deleterious results.
To clarify the functions and toxicities of various metals and their relationship to AD, specific
information on each metal is provided as follows:
Iron: Divalent iron (Fe2+) is the most abundant transition metal in the human brain. Iron is
present in vivo in both the ferrous (Fe2+) and ferric (Fe3+) valence states. Fe2+ is crucial for
neuronal processes such as myelination, synaptogenesis, and synaptic plasticity (SP). It has
been well documented that Fe2+ deficiency can induce a series of neurochemical alterations
that may eventually lead to cognitive deficits [42]. While essential for the maintenance of a
healthy brain, Fe2+ can also play a toxic role. It exacerbates damage to brain tissue following
processes such as stroke or trauma. A regional increase in Fe2+ within AD brains, compared
with healthy controls, is considered a key factor in neuronal atrophy. Accumulations of Fe2+
occur in the cerebral cortex, the hippocampus, and the basal nucleus of Meynert, where they
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co-localize with lesions, neurofibrillary tangles, and plaques. These are particularly important
areas in the clinical picture of AD because they are associated with the centers of memory and
thought that are gradually lost as AD progresses [42]. Given that Fe2+ is highly reactive, an
excess of this metal ion may result in the overproduction of reactive chemical species such as
•OH. Thus, FRs are responsible for oxidative stress, which is considered a primary contributing
factor in neurodegeneration [43].
Metal and
concentration in
AD brains (µM)
Physiological functions in
the brain
Brain areas where metal
is accumulated
Relationship with AD
Fe2+, 669, 694  Formation and maintenance
of the neuronal network
and neurotransmitter
synthesis. 
Hippocampus (wet tissue),
amygdala 
Generation of an excess of reactive
radical species leading to cell and
tissue damage. 
Cu2+, 57.7, 53.2,
10–100 
Cofactor and structural
component of enzymes.
Regulate synaptic function
myelination, synaptogenesis,
and synaptic plasticity. 
Hippocampus (wet tissue),
amygdala, cerebrospinal
fluid 
Copper in redox-active can catalyze
the production of hydroxyl radicals
(•OH) in a Fenton-like reaction.
May influence clearance of Aβ from
the brain at the level of the interface
between the blood and
cerebrovasculature in AD. 
Zn2+, 1000, 300  It is released from presynaptic
nerve terminals into the
synaptic cleft upon neuronal
activation and has been shown
to inhibit excitatory NMDA
receptors. 
Amyloid plaques, synaptic
cleft (during
neurotransmission) 
Aggregation of the Aβ peptides to
form oligomers and fibrils can be
rapidly induced in the presence of
zinc ions. 
Cr3+, 0.3, 0.4, 6.6  Carbohydrate metabolism and
normal insulin sensitivity. 
Brain insulin signal
transduction system. 
Hippocampus (wet tissue),
amygdala, cerebrospinal
fluid 
Reduction of the neuronal glucose
and energy metabolism. 
Cd2+, 0.25–250,
50–500 
It has not demonstrated a
function of brain metabolism. 
Parenchyma, cortical
neurons 
Increase of the blood-brain barrier
permeability and oxidative damage. 
Physiological functions, concentrations, brain areas of accumulation, and their relationship to AD.
Table 1. Principal metals involved in the development and progression of AD.
Copper: Copper in its divalent form (Cu2+) is found in several enzymes involved in important
biochemical pathways in neuronal and nonneuronal cells; these enzymes include SOD,
cytochrome-C oxidase, ceruloplasmin, and tyrosinase. Following NMDA receptor activa-
tion, Cu2+ is released from neurons; the released Cu2+ regulates neuronal activation by limit-
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ing Ca2+ entry into cells [44]. Astrocytes express several Cu2+-containing enzymes; however,
excess Cu2+ in astrocytes results in damage due to the binding of Cu2+ to Aβ. This can catalyze
the production of •OH in a Fenton-like reaction, favoring the establishment of oxidative stress
and cell damage [45]. For these reasons, the increase in the distribution of brain Cu2+ that occurs
in AD, producing concentrations ranging from 10 to 100 μM, could result in the establishment
of oxidative stress in areas that are important for memory and learning such as the hippo-
campus and amygdala (Table 1).
The diet is the principal source of Cu2+; in fact, studies by Sparks et al. show that the admin-
istration of trace amounts of this metal in drinking water may drive the accumulation of Aβ
levels in the brain by altering the level of the interface between the blood and the cerebrovas-
culature in an AD rabbit model [46]. This suggests that dietary metals may promote Aβ
accumulation [47].
Zinc: Under normal conditions, divalent zinc (Zn2+) is concentrated in the neocortex; its
concentration is closely regulated due to the potentially neurotoxic effects that occur under
conditions of Zn2+ excess or deficiency. Zn2+ also has a neuromodulatory role in that it inhibits
excitatory NMDA receptors, reaching concentrations of up to 300 μM [48, 49]. Religa et al.
demonstrated that Zn2+ levels increase in parallel with tissue amyloid levels. Zn2+ levels were
significantly elevated in the brains of the most severely demented patients with AD and in
cases that displayed an amyloid burden. In fact, high concentrations of this metal ion (up to 1
mM) have also been found within amyloid plaques [50]. The formation of Aβ aggregates occurs
rapidly in the presence of Zn2+ ions under physiological conditions in vitro [51]. Studies with
synthetic Aβ show that chelation chemistry helps solubilize amyloid plaques and that it has a
more marked effect on the extraction of Aβ than on the depletion of Cu2+ [52]. In addition,
elevated Zn2+ levels have been found in AD postmortem neocortical samples (Table 1) [53].
Chromium: Trivalent chromium (Cr3+) is essential for normal carbohydrate metabolism and
normal insulin sensitivity. It has been reported that Cr3+ and Zn2+ are of importance to the brain’s
insulin signal transduction system. A Cr3+-binding oligopeptide, which has been named
chromodulin, has been reported. In the presence of insulin, chromodulin causes an eightfold
stimulation of protein tyrosine kinase activity. Cr3+ ions increase insulin-stimulated tyrosine
phosphorylation and thereby modulate cellular insulin signaling. Within the pathogenesis of
AD, a reduction in neuronal glucose and energy metabolism is assumed. At the center of this
lies the disruption of insulin-signaling mechanisms. The results of current biochemical studies
indicate that Cr3+ and Zn2+ are important in the brain’s insulin signal transduction system [54].
Cadmium: Divalent cadmium (Cd2+) is a nonessential transition metal that is classified as a
carcinogen due to its long biological half-life. Prolonged exposure to Cd2+ has toxic effects due
to the accumulation of the metal in a variety of tissues, including the CNS. The principal effect
of Cd2+ in the CNS is the induction of oxidative damage in cells. Increasing evidence has
demonstrated that Cd2+ is a possible etiological factor for neurodegenerative diseases such as
AD. Cerebral cortical neurons have been identified as targets of Cd2+-mediated toxicity and
Cd2+-induced cell apoptosis [55].
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3.2. Interaction of metals with amyloid beta and hydrogen peroxide production
Senile plaques are composed primarily of extraneuronal-aggregated Aβ, microglia, degener-
ated neurons, and relatively high amounts of redox-active metals such as Cu2+, Fe2+, and Zn2+.
Accurate determination of the redox potentials of Aβ and its metal complexes will certainly
help unravel their roles in oxidative stress, metal homeostasis, detoxification, and Aβ aggre-
gation/fibril formation. For these reasons, a number of techniques have been employed to
determine the amino acids involved in the recognition of metals by Aβ. It is generally accepted
that metal ions are bound to the histidine residues at positions 6, 13, and 14 [56]. Several studies
have demonstrated that the interaction of Cu2+, Zn2+, Fe3+, and Al3+ with Aβ is maintained by
their coordination with His13-His14 of the peptide. The interaction is also maintained by a
fourth element represented by a donor atom that can come from the aspartate at position 1 or
the tyrosine at position 10, thus forming a tetragonal complex. In fact, marked inhibition of
cortical amyloid accumulation by DP-109, a lipophilic metal chelator, has been shown [57].
An important aspect of the binding of Cu2+ to Aβ is that the complex retains its redox activity
and is able to produce H2O2. As the principal ROS in living organisms, H2O2 acts as a second
messenger in cellular signal transduction under physiological conditions. However, the
overproduction of H2O2 results in the formation of high levels of •OH and consequent oxidation
of the peptide, which can be detected by the formation of carbonyl groups. It was demonstrated
that this oxidation increases as the Cu2+:peptide ratio increases and that it is accompanied by
changes in the morphology of the aggregates as determined by AFM [58].
It has been shown that the coordination of Zn2+ with His13 of Aβ is critical to the metal ion-
induced aggregation of Aβ [59]. NMR and circular dichroism (CD) studies of metal-Aβ
complexes show that Zn2+ binding is dominated by intermolecular coordination and by the
formation of polymeric species, including monomeric Zn2+-Aβ and various Zn2+-Aβ oligomeric
complexes and aggregates. However, Zn2+-Aβ complex formation is high only in brain areas
containing synapses. There, the initial binding of Zn2+ to Aβ induces transformation of the
peptide to an oligomeric or polymeric complex with increased Zn2+-binding affinity, potenti-
ating the effect of the metal on Aβ and possibly enabling Zn2+ to act as a seeding factor in
amyloid plaque formation [60]. When aggregates are prepared with Cu2+ and Zn2+ ions, the
ratio of Cu2+:Zn2+ becomes an important factor in H2O2 generation, the formation of carbonyl
groups in the peptide, and aggregate morphology. In fact, Aβ fibrils can hydrolyze H2O2 and
generate damage by •OH production [61].
Fe2+ is able to bind to Aβ, and increased amounts of redox-active iron that can generate an
elevated amount of ROS have been found in the brains of AD patients; however, it is not clear
how this redox-active Fe2+ is produced. It was postulated that Aβ may act by binding the Fe3+
and reducing it to pathological Fe2+ that is capable of inducing oxidative stress; this would
suggest that Aβ possesses a strong reducing capacity for iron and that it acts as a metalloprotein
capable of binding the metal ion. The interactions between iron and Aβ are governed by
histidines 6, 13, and 14. These amino acid residues could coordinate a shared metal ion and
generate a redox-active complex. An alternative explanation might be that an oxidative
reaction that uses histidine as a substrate occurs in the presence of Aβ, thereby generating toxic
oxygen species [62]. The contribution of each histidine residue to Aβ oligomerization and
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toxicity is different; it is thought that the His6 residue is important for beginning the Aβ
dimerization process and that His13 and His14 are not. However, the latter residues could be
important in producing the peptide conformations responsible for the Aβ-iron effects [63].
The reduction of metals (principally Cu2+) by Aβ causes the oxidation of Met35, resulting in
the production of H2O2 [64]. In addition, during the catalytic production of H2O2 by Aβ1–42 and
Cu2+, the participation of Tyr10 is important because when this amino acid is substituted by
alanine (Y10A) there is a significant decrease in the ability of Aβ to reduce Cu2+. Here, it is
important to note that the reduction of the metal and H2O2 production allow the formation of
the •OH radical by a Fenton-like reaction.
3.3. Fenton reaction
All the available evidence indicates that the Fenton reaction is important during Aβ aggre-
gation and during metal dyshomeostasis in AD. This reaction was first described by H.J.H.
Fenton as the strong oxidation effect of Fe2+-H2O2 mixtures on organic compounds in a work
entitled “Oxidation of tartaric acid in the presence of iron” [65]. Currently, the combination
of Fe2+-H2O2 is known as Fenton chemistry, the Fenton reaction, or Fenton reagent.
The Fenton reaction can be written as follows (4):
2 3
2 2Fe H O Fe HO + O+ H+ + -+ ® g (4)
During AD, the Fenton reaction occurs due to the presence of excessive levels of active redox
metals and the generation of H2O2 by the reaction of Aβ1–42 with the metals. Subsequently, •OH
are formed by the interaction of Aβ1–42 and Fe3+ or Cu2+. Several years ago, a speculative
mechanism was proposed by which Aβ interaction with metals could produce ROS. In that
mechanism, the binding of the metal is followed by the binding of oxygen to the metal via a
peroxo bridge and O2•− production; the O2•− are then converted to H2O2, which reacts with
metals and produces •OH [66].
Furthermore, it has been proposed that during the Fenton reaction an intermediate such as
ferryl ion [Fe(IV)=O]2+, a highly reactive oxidant that is able to undergo a reaction involving
single-electron hydrogen abstraction and two-electron oxidation, is formed; however, this
intermediate is not produced during Aβ1–42 aggregation because it is formed during the
reaction of Fe2+ complexes with H2O2 in the presence of organic substrates and a porphyrin
complex. Therefore, •OH are produced when aggregated Aβ1–42 interacts with metals. How-
ever, several in vitro studies have shown that •OH can be generated when Fe3+ is reduced in
the presence of reducing agents such as ascorbic acid (5) or in the absence of redox agents in
a reaction in which one electron from -OH (from the water self-ionization reaction) is trans-
ferred to Fe3+, yielding Fe2+ and •OH (6) [67]. This reaction also occurs in AD due to the presence
of high levels of metals and the consequent production of •OH; this promotes Aβ1–42 aggrega-
tion and consequently increases ROS production, creating a vicious cycle.
Involvement of Free Radicals in the Development and Progression of Alzheimer’s Disease
http://dx.doi.org/10.5772/64708
259
3 2Fe Asc Fe Asc+ - + -+ ® + g (5)
3 2Fe HO Fe HO+ - ++ ® + g (6)
The Fenton reaction can also occur in the presence of other metals via a Fenton reaction or a
Fenton like-reaction, as shown below (7):
( 1)
2 2M H O M HO HOn n+ + + -+ ++ ® g (7)
where M is the metal (such as copper, which can also be reduced by Aβ1–42) that is oxidized in
the reaction. When M = Fe2+, the reaction above is known as Fenton reaction; when M = any
other metal, the reaction is known as Fenton-like reaction.
In AD, it has been suggested that •OH formation damages biomolecules such as lipids,
proteins, and nucleic acids due to the ability of •OH to catalyze reactions such as hydrogen
abstraction, addition reactions, and oxidation reactions. Hydrogen abstraction is one of the
most important mechanisms because in this reaction the •OH damages lipids in the brain and,
as was mentioned previously, the brain has a high content of lipids. Lipoperoxidation (LPO)
is the process by which •OH abstract hydrogen from unsaturated fatty acids, forming alkyl
radicals. The principal products of LPO are aldehydes as malondialdehyde (MDA) and
propanal, hexanal and 4-hydroxynonenal (4-HNE). LPO of oleic acid in the brain occurs by
abstraction of the hydrogens in the ninth and tenth positions; secondary reactions include
hydrogen abstraction by alkoxy radicals (RO•) and peroxyl radicals (ROO•) at the tertiary
carbon atoms. Then, alkyl radicals (R•) and ROO• are produced by ROS.
4. Damage produced by FRs during Alzheimer’s disease
The brain is particularly vulnerable to oxidative stress because of its high metabolic rate, which
utilizes 20% of the body’s basal oxygen consumption. In addition, the brain has limited
antioxidant defenses compared with other organs and high levels of transition metals,
principally redox-active Cu2+ and Fe2+; defective regulation of the levels of these metals can
lead to reaction with O2 and the production of ROS, resulting in cellular toxicity. Neurons are
vulnerable to attack by FRs due to their lower glutathione content in comparison with other
cells, their high proportion of polyunsaturated fatty acids susceptible to oxidation, and the fact
that their metabolism requires substantial quantities of oxygen. The oxidation of biomolecules
such as proteins, lipids, and DNA, and mitochondrial damage have consequences that are
deleterious to neurons, including the loss of cell potential, the accumulation of excitotoxic
glutamate, decreased glucose availability, decreased intracellular communication, and
increased neurotoxicity [68].
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A large number of biological sources are thought to play important roles in FR production in
AD. As mentioned above, some transition metals are increased in AD brains and are present
in a redox-active state [69]. Fe2+ catalyzes the formation of •OH from H2O2 by the Fenton
reaction in the brains of patients with AD due to the imbalance in metal concentrations, and
together with the H2O2 produced by Aβ aggregation it is possible to generate •OH, which
results in the oxidation of lipids, proteins, and DNA [70]. Recent histochemical studies have
demonstrated that the detection of redox activity in AD lesions is inhibited by prior exposure
of tissue sections to Fe2+- and Cu2+-selective chelators. The activity can be reinstated following
reexposure of the chelator-treated sections to either copper or iron salts, suggesting that the
redox imbalance in AD is dependent on these metals. It is probable that the accumulation of
Fe2+ and Cu2+ is a major source of the production of reactive oxygen, which is in turn responsible
not only for the numerous oxidative stress markers that appear on senile plaques but also for
the more global oxidative stress parameters observed in AD [71].
Activated microglia, such as those that surround most senile plaques [72] are a source of the
reactive nitrogen species (RNS) NO and the ROS O2•−, which can react to form ONOO−, leaving
nitrotyrosine as an identifiable marker [73], as shown in Figure 4.
Figure 4. ROS and RNS produced after the activation of microglial cells by Aβ1–42. ROS have effects on biomolecules
such as lipids, proteins, and nucleic acids.
Several studies have reported that pro-inflammatory molecules and ROS secreted from fibrillar
Aβ-stimulated microglia lead to neuronal apoptosis [74]. In addition, neurons, microglia, and
astrocytes are capable of generating substantial amounts of NO through the iNOS [75]. Fibrillar
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Aβ peptides stimulate iNOS and NO production through the NADPH-dependent oxidative
deamination of L-arginine [76]. Microglial/neuronal coculture studies reveal that the NO
released from Aβ-stimulated microglia causes neuronal cell death. In addition, iNOS has been
reported to act synergistically to kill neurons through the formation of ONOO−. This RNS is a
potent oxidant with biological reactivity similar to that of •OH. ONOO- promotes the tyrosine
nitration and nitrosylation of cysteines within cellular proteins. The addition of nitrite (NO2−)
to tyrosine residues is extremely detrimental because it leads to protein and enzyme dysfunc-
tion and the eventual death of cultured neurons [77]. Taken together, these data suggest that
Aβ-stimulated production of ONOO− plays an important role in the pathogenesis of oxidative
damage in the AD brain.
The damage to lipids caused by FRs is evidenced by LPO, which has been demonstrated widely
in all areas of the brain and shown to be higher in the hippocampus, the piriform cortex, the
frontal lobe, and the occipital cortex [78]. Furthermore, LPO markers have been found in the
cerebrospinal fluid (CSF) and urine of patients with AD, and their levels tend to increase with
the progression of the disease [79]. Analysis of transgenic mice (Tg2576) that display oxidative
damage similar to that found in the brains of AD patients revealed an elevation in oxidative
stress markers preceding amyloid formation and increasing amyloid pathology [80]. Data from
humans and transgenic mice indicate that elevated oxidative stress is an early event in AD
pathogenesis.
Advanced glycation end products (AGEs) are involved in AD through several mechanisms.
AGEs, which are produced by the interaction of carbohydrates and proteins, stimulate the
production of ROS in the presence of transition metals by the establishment of redox cycling.
In addition, both Aβ and AGEs activate receptors such as the receptor for advanced glycation
end products (RAGEs) and the class A scavenger receptor and thereby increase ROS produc-
tion [81].
Proteins damaged by ROS can be measured in plasma, serum, CSF, and brain tissue. Studies
by Smith et al. have demonstrated an increase in the products of protein oxidation in the
hippocampus of patients with AD, which showed neurodegenerative changes in comparison
with normal and aged subjects [82].
The production of ROS through peptidyl radicals associated with Aβ contributes to Aβ
aggregation; it was demonstrated that protein oxidation promotes the formation of protein
aggregates. In addition, Aβ causes alterations in several transmembrane proteins present in
neurons and glial cells, including ATPases, glutamate transporters, glucose transporters and
guanosine triphosphate (GTP)-coupled transmembrane-signaling proteins, resulting in
multiple changes in cellular physiology [83].
The type of damage found in macromolecules such as lipids, proteins, and carbohydrates in
patients with AD has also been observed in DNA. Mecoccin et al. showed a 10-fold increase
in the oxidation of mitochondria and nuclear DNA in brain samples from AD patients [84].
The formation of ROS by any of several possible mechanisms results in damage to neurons.
The cholinergic system is the principal neurotransmission system that is affected by the
production of oxidative stress. It was postulated that •OH may decrease the activity of AChE
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by modifying the amino acid residues, which form the anionic site that recognizes the natural
substrate, ACh [85].
A large body of evidence implicates compromised antioxidant defense systems as a contribu-
ting factor in AD pathogenesis; however, studies of antioxidant enzymes in AD have not shown
a consistent pattern. Glutathione (c-glutamyl-cysteinyl-glycine; GSH) is an abundant cellular
antioxidant. Thiol-reduced GSH normally accounts for the majority (>98%) of total cellular
glutathione, but it can also exist as oxidized glutathione disulfide (GSSG) or glutathione
adducts. Glutathione peroxidase (GPx) catalyzes the oxidation of GSH to GSSG, whereas the
reverse reaction is carried out by glutathione reductase (GR), which requires NADPH. Coupled
to the oxidation of GSH, GPx can reduce H2O2, highlighting the importance of both GPx and
GR in maintaining the cellular redox state. Indeed, the measurement of erythrocyte levels of
GSH, expressed as the ratio of GSH/GSSG, provides a dynamic marker of oxidative stress in
vivo [86, 87]. Lovell et al. found significantly elevated activity of GPx in the hippocampus, of
GR in the hippocampus and amygdala, and of catalase (CAT) activity in the hippocampus and
superior and middle temporal gyri in AD subjects compared with normal control subjects [88].
These changes were present in the medial temporal lobe structures where LPO was signifi-
cantly increased, suggesting a compensatory rise in antioxidant activity in response to
increased FR generation in these regions in AD. SOD levels were elevated in all brain regions
in AD. CAT was elevated in the amygdala in AD in one study [88]. Marcus et al. demonstrated
modifications in the activities of antioxidant enzymes in AD brains. The results showed a
decrease in SOD activity in AD frontal and AD temporal cortex, whereas CAT activity
decreased in AD temporal cortex. By contrast, these investigators found no differences in GPx
activity. The results obtained in these studies show that alterations in the antioxidant enzymes
in the brains of patients with AD are most significant in the temporal cortex [89]. For these
reasons, the use of antioxidants represents a logical approach to the treatment of AD. This
hypothesis is very attractive because most antioxidant compounds have a wide safety margin.
The hypothesis has been evaluated under experimental and clinical conditions. Crapper
McLachlan et al. [90] showed that the prolonged administration of an iron-chelating agent,
desferrioxamine, slowed the development of the disease. Vitamin E, selegiline, and Ginkgo
biloba extract were evaluated in clinical studies of AD and produced beneficial results [91].
These findings provide important evidence supporting the hypothesis that antioxidants may
be capable of slowing the pathogenic process of AD. In addition, a decrease in the incidence
of AD in patients treated chronically with non-steroidal anti-inflammatory drugs (NSAIDs)
has been demonstrated; this could slow the progress of the disease by decreasing the produc-
tion of prostaglandins [92].
5. Determination of free radicals in in vivo and in vitro models of
Alzheimer’s disease
As previously mentioned, the production of high levels of ROS is related to the establishment
and progression of AD. Among these ROS are O2•−, H2O2, •OH, NO, and ONOO−, which can
be produced by several mechanisms (direct ROS production by Aβ1–42 oligomers, interaction
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of Aβ with metals, microglial activation, etc.). For these reasons, a variety of techniques have
been employed to determine the species and amounts of ROS in biological samples of patients
with AD and in samples from animal models.
5.1. Electronic paramagnetic resonance
Among ROS, O2•− and •OH are molecules with unpaired electrons that react rapidly with
various biomolecules. To quantify these molecules by electron paramagnetic resonance (EPR),
it is necessary to employ compounds that increase the half-lives of the unpaired electrons. The
most common compounds employed for this purpose are 5,5-dimethyl-1-pyrroline N-oxide
(DMPO), N-tertiary-butyl-nitrone (PBN), and 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO),
all of which react with the unpaired electron of a specific FR and form a complex that is
sufficiently stable to be detected by EPR. This technique allows the quantification of FRs in a
wide variety of samples obtained in in vivo and in vitro studies. The nitroxide MCP (3-
methoxidecarnonyl-2,2,5,5,-tetramethylpyrrolidine-1-yloxy), which permeates the blood-
brain barrier, has been used as a spin probe to noninvasively evaluate redox status in the brains
of AD transgenic model mice (APdE9), allowing the measurement of the generation of FRs
during the development of the disease [93]. In addition, with the use of DMPO an increase in
the production of •OH radicals in activated microglial cells in in vitro studies was demonstrat-
ed [94].
Although the EPR technique is of great help in identifying and quantifying FRs, its use is
limited due to the fact that it requires an EPR spectrometer, which is expensive. If an EPR is
not available, other techniques can be used to determine the amount of ROS produced;
however, one disadvantage of these techniques is that they require samples from animals that
must therefore be sacrificed.
5.2. Superoxide anion determinations
There are several techniques that permit the quantification of O2•− in biological samples; these
include cytochrome C, WST-1 [2-(4-iodophenyl)-3-(4-nitrophenyl-5-(2,4-disulfophenyl)-2H-
tetrazolium monosodium salt], lucigenin, luminol, and others. Several of these techniques are
described below.
Cytochrome C. This technique has been used to quantify extracellular O2•− in cultures of
microglial cells obtained from neonatal rats stimulated with lipopolysaccharide (LPS). The
principle of the method is based on the reducing properties of O2•−. O2•− donates an electron
to ferricytochrome C, reducing ferrocytochrome C and increasing its absorbance at 550 nm.
This method presents some limitations if the sample contains high amounts of O2•− because
the cytochrome can be reduced by various molecules such as ascorbate, glutathione, and
several reductases that are able to produce ferrocytochrome C [95].
Tetrazolium salt (WST-1). The reduction of WST-1 to a water-soluble yellow formazan by O2•−
can be measured by spectrophotometry (Figure 5A). This method has been compared with the
ferricytochrome C reduction method in which xanthine/xanthine oxidases are used to
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generate O2•−; it was demonstrated that WST-1 generated an approximately twofold greater
increase in absorbance than ferricytochrome C at their respective wavelengths [96].
Figure 5. Reactions for the determination of O2•− and H2O2. (A) Reduction of WST-1 by O2•− to a water-soluble yellow
formazan. (B) Reduction of lucigenin by O2•− to a lucigenin cation radical. (C) Oxidation of luminol by H2O2. (D) Oxida-
tion of Amplex red by H2O2 in the presence of HRP to produce resorufin.
Lucigenin and luminol. These substances are selectively employed to determine the amounts of
extracellular O2•− and intracellular O2•− and H2O2 by chemiluminescence. Lucigenin is selective
for O2•−, and luminol is selective for O2•− and H2O2. Lucigenin is reduced by O2•− to a lucigenin
cation radical independently of peroxidase activity (Figure 5B), and luminol is oxidized using
a peroxidase such as myeloperoxidase (MPO) or horseradish peroxidase (HRP) (Figure 5C).
5.3. Hydrogen peroxide determination
To determine the amount of H2O2, electrodes can be used, and the amount of H2O2 can then be
determined polarigraphically. The sensitivity of the electrode allows precise and rapid
measurement of extracellular H2O2. Other probes include the use of targets and are based on
the ability of H2O2 to oxidize molecules such as Amplex red (N-acetyl-3,7-dihydroxyphenox-
azine), scopoletin, and homovanillic acid in the presence of HRP. There are also many other
techniques that allow the determination of the amount of H2O2, such as aryl-borate-based
probes, peroxy Lucifer, and others; however, Amplex red is one of the most used. Amplex red
is a non-fluorescent compound that is oxidized by H2O2 in the presence of HRP to produce
resorufin, which is colored and highly fluorescent at 587 nm (Figure 5D). Amplex red has been
Involvement of Free Radicals in the Development and Progression of Alzheimer’s Disease
http://dx.doi.org/10.5772/64708
265
used to measure H2O2 production by microglial cells and also directly in vitro to measure
H2O2 production by Aβ during its interaction with metals such as copper [97].
6. Conclusion
It has been demonstrated that Aβ1–42 is one of the principal biomolecules that contributes to
the development and progression of AD due to its ability to generate ROS by its interaction
with metals and also due to its ability to activate specific cells, producing neuroinflammation
and consequently neurodegeneration. Therefore, therapeutic treatments to avoid Aβ produc-
tion should be developed by the design of selective inhibitors of the β-secretase BACE-1.
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